Summary

Global anti-fungal drugs market is expected to reach USD28484.69 million by 2026, growing at CAGR of 10.39% over the forecast period. Fungal infections can lead to diseases including fungal pneumonia, candidiasis, mucormycosis, among others and these fungal infections require the dosage of anti-fungal drugs to ensure effective treatment. The increasing prevalence of fungal infections is considered the primary driver for the market growth in the forecast period. The rise in awareness levels among patients regarding the adverse effect of fungal infection on the human body is significantly accelerating the demand for anti-fungal drugs around the world. An increase in government funds and investments to promote research and development activities to formulate anti-fungal drugs is fueling the market growth. An increase in the use of anti-fungal drugs coupled with the rising number of anti-fungal drugs available over-the-counter is expected to boost the market demand. With the surge in popularity of over-the-counter drugs such as ketoconazole, miconazole, econazole, amorolfine, several patients are preferring over-the-counter drugs. The rise in onychomycosis cases, which is a fungal infection affecting fingers and toenails is also considered a major driver responsible for the high demand for anti-fungal drugs.

The global anti-fungal drugs market is segmented into drug class, indication, infection type, route of administration, end-user, distribution channel, regional distribution, and company. Based on drug class, market is further divided into azoles, echinocandins, polyenes, allylamines and others. The azoles segment is expected to dominate the anti-fungal drugs market in the forecast period owing to their use in treatment of almost all the indications. Based on indication, the market is segmented into candidiasis, aspergillosis, dermatophytosis, mucormycosis, and others. The candidiasis segment is expected to dominate the market owing to high cases globally associated with the fungal species.

Based on regional analysis, North America is expected to dominate the anti-fungal drugs market for the next five years owing to the presence of major market players in the region. The high prevalence of fungal infections in the region is another crucial factor aiding the market growth. Well-developed healthcare infrastructure and favorable government healthcare policies are the other significant factors bolstering the market growth.
The major players operating in the global anti-fungal drugs market are Astellas Pharma Inc., GlaxoSmithKline Plc, Bayer AG, Dr. Reddy's Laboratories Ltd., Gilead Sciences Inc., Janssen Pharmaceuticals Inc. (Johnson & Johnson), Pfizer Inc., Sanofi S.A., Merck & Co., Inc., Glenmark Pharmaceuticals Ltd., Sun Pharmaceuticals Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc. (Mylan Laboratories Inc.), Cipla Ltd., Zydus Cadila Ltd., Lupin Ltd., Torrent Pharmaceuticals Ltd, Abbott Laboratories Inc., Novartis AG, Galderma SA among others. Major companies are developing advanced technologies and launching new anti-fungal drugs to stay competitive in the market. Other competitive strategies include mergers & acquisitions and new product developments.
Years considered for this report:
Historical Years: 2016-2019
Base Year: 2020
Estimated Year: 2021
Forecast Period: 2022–2026
Objective of the Study:
• To analyze the historical growth in the market size of global anti-fungal drugs market from 2016 to 2020.
• To estimate and forecast the market size of global anti-fungal drugs market from 2021 to 2026 and growth rate until 2026.
• To classify and forecast global anti-fungal drugs market based on drug class, indication, infection type, route of administration, end user, distribution channel, regional distribution, and company.
• To identify dominant region or segment in the global anti-fungal drugs market.
• To identify drivers and challenges for global anti-fungal drugs market.
• To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global anti-fungal drugs market.
• To identify and analyze the profile of leading players operating in global anti-fungal drugs market.
• To identify key sustainable strategies adopted by market players in global anti-fungal drugs market.
TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers who could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufacturers, distribution channels and presence of all major players across the globe.
TechSci Research calculated the market size of global anti-fungal drugs market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of various segments for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.
Key Target Audience:
• Anti-fungal drug manufacturing companies
• Market research and consulting firms
• Government bodies such as regulating authorities and policy makers
• Organizations, forums and alliances related to anti-fungal drugs market
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers and partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.
Report Scope:
In this report, global anti-fungal drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
• Global Anti-Fungal Drugs Market, By Drug Class:
o Azoles
o Echinocandins
o Polyenes
o Allylamines
o Others
• Global Anti-Fungal Drugs Market, By Indication:
o Candidiasis
o Aspergillosis
o Mucormycosis
o Dermatophytosis
o Others
• Global Anti-Fungal Drugs Market, By Infection Type:
o Superficial Fungal Infection
o Systemic Fungal Infection
• Global Anti-Fungal Drugs Market, By Route of Administration:
o Topical
o Oral
o Parenteral
o Others
• Global Anti-Fungal Drugs Market, By End-User:
o Homecare
o Hospitals
o Clinics
o Others
• Global Anti-Fungal Drugs Market, By Distribution Channel:
o Retail Pharmacy
o Hospital Pharmacy
o Online Pharmacy
• Global Anti-Fungal Drugs Market, By Region:
o North America
 United States
 Mexico
 Canada
o Europe
 Russia
 Germany
 France
 United Kingdom
 Italy
 Spain
 Poland
o Asia-Pacific
 India
 China
 Indonesia
 Japan
 South Korea
 Malaysia
 Australia
o South America
 Brazil
 Colombia
 Argentina
o Middle East & Africa
 Nigeria
 Turkey
 South Africa
 Saudi Arabia
 UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in global anti-fungal drugs market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
2. Research Methodology
3. Impact of COVID-19 on Global Anti-Fungal Drugs Market
4. Executive Summary
5. Voice of Customer
5.1. Brand Awareness
5.2. Factors Contributing to the Prevalence of Fungal Diseases
5.3. Commonly Observed Fungal Diseases
6. Global Anti-Fungal Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Others)
6.2.2. By Indication (Candidiasis, Aspergillosis, Mucormycosis, Dermatophytosis, Others)
6.2.3. By Infection Type (Superficial Fungal Infection v/s Systemic Fungal Infection)
6.2.4. By Route of Administration (Topical, Oral, Parenteral, Others)
6.2.5. By End User (Homecare, Hospitals, Clinics, Others)
6.2.6. By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy)
6.2.7. By Region
6.2.8. By Company (2020)
6.3. Product Market Map
7. North America Anti-Fungal Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Indication
7.2.3. By Infection Type
7.2.4. By Route of Administration
7.2.5. By End User
7.2.6. By Distribution Channel
7.2.7. By Country
7.3. North America: Country Analysis
7.3.1. United States Anti-Fungal Drugs Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Indication
7.3.1.2.3. By Infection Type
7.3.1.2.4. By Route of Administration
7.3.1.2.5. By End User
7.3.1.2.6. By Distribution Channel
7.3.2. Mexico Anti-Fungal Drugs Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Indication
7.3.2.2.3. By Infection Type
7.3.2.2.4. By Route of Administration
7.3.2.2.5. By End User
7.3.2.2.6. By Distribution Channel
7.3.3. Canada Anti-Fungal Drugs Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Indication
7.3.3.2.3. By Infection Type
7.3.3.2.4. By Route of Administration
7.3.3.2.5. By End User
7.3.3.2.6. By Distribution Channel
8. Europe Anti-Fungal Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Indication
8.2.3. By Infection Type
8.2.4. By Route of Administration
8.2.5. By End User
8.2.6. By Distribution Channel
8.2.7. By Country
8.3. Europe: Country Analysis
8.3.1. Russia Anti-Fungal Drugs Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Indication
8.3.1.2.3. By Infection Type
8.3.1.2.4. By Route of Administration
8.3.1.2.5. By End User
8.3.1.2.6. By Distribution Channel
8.3.2. Germany Anti-Fungal Drugs Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Indication
8.3.2.2.3. By Infection Type
8.3.2.2.4. By Route of Administration
8.3.2.2.5. By End User
8.3.2.2.6. By Distribution Channel
8.3.3. France Anti-Fungal Drugs Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Indication
8.3.3.2.3. By Infection Type
8.3.3.2.4. By Route of Administration
8.3.3.2.5. By End User
8.3.3.2.6. By Distribution Channel
8.3.4. United Kingdom Anti-Fungal Drugs Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Class
8.3.4.2.2. By Indication
8.3.4.2.3. By Infection Type
8.3.4.2.4. By Route of Administration
8.3.4.2.5. By End User
8.3.4.2.6. By Distribution Channel
8.3.5. Italy Anti-Fungal Drugs Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Class
8.3.5.2.2. By Indication
8.3.5.2.3. By Infection Type
8.3.5.2.4. By Route of Administration
8.3.5.2.5. By End User
8.3.5.2.6. By Distribution Channel
8.3.6. Spain Anti-Fungal Drugs Market Outlook
8.3.6.1. Market Size & Forecast
8.3.6.1.1. By Value
8.3.6.2. Market Share & Forecast
8.3.6.2.1. By Drug Class
8.3.6.2.2. By Indication
8.3.6.2.3. By Infection Type
8.3.6.2.4. By Route of Administration
8.3.6.2.5. By End User
8.3.6.2.6. By Distribution Channel
8.3.7. Poland Anti-Fungal Drugs Market Outlook
8.3.7.1. Market Size & Forecast
8.3.7.1.1. By Value
8.3.7.2. Market Share & Forecast
8.3.7.2.1. By Drug Class
8.3.7.2.2. By Indication
8.3.7.2.3. By Infection Type
8.3.7.2.4. By Route of Administration
8.3.7.2.5. By End User
8.3.7.2.6. By Distribution Channel
9. Asia-Pacific Anti-Fungal Drugs Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Class
9.2.2. By Indication
9.2.3. By Infection Type
9.2.4. By Route of Administration
9.2.5. By End User
9.2.6. By Distribution Channel
9.2.7. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. India Anti-Fungal Drugs Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Class
9.3.1.2.2. By Indication
9.3.1.2.3. By Infection Type
9.3.1.2.4. By Route of Administration
9.3.1.2.5. By End User
9.3.1.2.6. By Distribution Channel
9.3.2. China Anti-Fungal Drugs Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Class
9.3.2.2.2. By Indication
9.3.2.2.3. By Infection Type
9.3.2.2.4. By Route of Administration
9.3.2.2.5. By End User
9.3.2.2.6. By Distribution Channel
9.3.3. Indonesia Anti-Fungal Drugs Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Class
9.3.3.2.2. By Indication
9.3.3.2.3. By Infection Type
9.3.3.2.4. By Route of Administration
9.3.3.2.5. By End User
9.3.3.2.6. By Distribution Channel
9.3.4. Japan Anti-Fungal Drugs Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Drug Class
9.3.4.2.2. By Indication
9.3.4.2.3. By Infection Type
9.3.4.2.4. By Route of Administration
9.3.4.2.5. By End User
9.3.4.2.6. By Distribution Channel
9.3.5. South Korea Anti-Fungal Drugs Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Drug Class
9.3.5.2.2. By Indication
9.3.5.2.3. By Infection Type
9.3.5.2.4. By Route of Administration
9.3.5.2.5. By End User
9.3.5.2.6. By Distribution Channel
9.3.6. Malaysia Anti-Fungal Drugs Market Outlook
9.3.6.1. Market Size & Forecast
9.3.6.1.1. By Value
9.3.6.2. Market Share & Forecast
9.3.6.2.1. By Drug Class
9.3.6.2.2. By Indication
9.3.6.2.3. By Infection Type
9.3.6.2.4. By Route of Administration
9.3.6.2.5. By End User
9.3.6.2.6. By Distribution Channel
9.3.7. Australia Anti-Fungal Drugs Market Outlook
9.3.7.1. Market Size & Forecast
9.3.7.1.1. By Value
9.3.7.2. Market Share & Forecast
9.3.7.2.1. By Drug Class
9.3.7.2.2. By Indication
9.3.7.2.3. By Infection Type
9.3.7.2.4. By Route of Administration
9.3.7.2.5. By End User
9.3.7.2.6. By Distribution Channel
10. South America Anti-Fungal Drugs Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Class
10.2.2. By Indication
10.2.3. By Infection Type
10.2.4. By Route of Administration
10.2.5. By End User
10.2.6. By Distribution Channel
10.2.7. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Anti-Fungal Drugs Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Class
10.3.1.2.2. By Indication
10.3.1.2.3. By Infection Type
10.3.1.2.4. By Route of Administration
10.3.1.2.5. By End User
10.3.1.2.6. By Distribution Channel
10.3.2. Colombia Anti-Fungal Drugs Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Class
10.3.2.2.2. By Indication
10.3.2.2.3. By Infection Type
10.3.2.2.4. By Route of Administration
10.3.2.2.5. By End User
10.3.2.2.6. By Distribution Channel
10.3.3. Argentina Anti-Fungal Drugs Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Class
10.3.3.2.2. By Indication
10.3.3.2.3. By Infection Type
10.3.3.2.4. By Route of Administration
10.3.3.2.5. By End User
10.3.3.2.6. By Distribution Channel
11. Middle East and Africa Anti-Fungal Drugs Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Drug Class
11.2.2. By Indication
11.2.3. By Infection Type
11.2.4. By Route of Administration
11.2.5. By End User
11.2.6. By Distribution Channel
11.2.7. By Country
11.3. MEA: Country Analysis
11.3.1. Nigeria Anti-Fungal Drugs Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Drug Class
11.3.1.2.2. By Indication
11.3.1.2.3. By Infection Type
11.3.1.2.4. By Route of Administration
11.3.1.2.5. By End User
11.3.1.2.6. By Distribution Channel
11.3.2. Turkey Anti-Fungal Drugs Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Drug Class
11.3.2.2.2. By Indication
11.3.2.2.3. By Infection Type
11.3.2.2.4. By Route of Administration
11.3.2.2.5. By End User
11.3.2.2.6. By Distribution Channel
11.3.3. South Africa Anti-Fungal Drugs Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Drug Class
11.3.3.2.2. By Indication
11.3.3.2.3. By Infection Type
11.3.3.2.4. By Route of Administration
11.3.3.2.5. By End User
11.3.3.2.6. By Distribution Channel
11.3.4. Saudi Arabia Anti-Fungal Drugs Market Outlook
11.3.4.1. Market Size & Forecast
11.3.4.1.1. By Value
11.3.4.2. Market Share & Forecast
11.3.4.2.1. By Drug Class
11.3.4.2.2. By Indication
11.3.4.2.3. By Infection Type
11.3.4.2.4. By Route of Administration
11.3.4.2.5. By End User
11.3.4.2.6. By Distribution Channel
11.3.5. UAE Anti-Fungal Drugs Market Outlook
11.3.5.1. Market Size & Forecast
11.3.5.1.1. By Value
11.3.5.2. Market Share & Forecast
11.3.5.2.1. By Drug Class
11.3.5.2.2. By Indication
11.3.5.2.3. By Infection Type
11.3.5.2.4. By Route of Administration
11.3.5.2.5. By End User
11.3.5.2.6. By Distribution Channel
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends & Developments
14. Competitive Landscape
14.1. Competition Outlook
14.2. Players Profiled
14.2.1. Astellas Pharma Inc.
14.2.2. GlaxoSmithKline Plc
14.2.3. Bayer AG
14.2.4. Dr. Reddy's Laboratories Ltd.
14.2.5. Gilead Sciences Inc.
14.2.6. Janssen Pharmaceuticals Inc. (Johnson & Johnson)
14.2.7. Pfizer Inc.
14.2.8. Sanofi S.A.
14.2.9. Merck & Co., Inc.
14.2.10. Glenmark Pharmaceuticals Ltd.
14.2.11. Sun Pharmaceuticals Industries Ltd.
14.2.12. Teva Pharmaceutical Industries Ltd.
14.2.13. Viatris Inc. (Mylan Laboratories Inc.)
14.2.14. Cipla Ltd.
14.2.15. Zydus Cadila Ltd.
14.2.16. Lupin Ltd.
14.2.17. Torrent Pharmaceuticals Ltd
14.2.18. Abbott Laboratories Inc
14.2.19. Novartis AG
14.2.20. Galderma SA
15. Strategic Recommendations
16. About Us & Disclaimer